Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban

References

• Agnelli G, Becattini C, Franco L. New oral anticoagulants for the treatment of venous thromboembolism. Best Pract Res Clin Haematol 2013;26:151–61
   PubMed Web of Science ®Google Scholar
• Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011;86:217–20
   PubMed Web of Science ®Google Scholar
• Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38:S495–501
   PubMed Web of Science ®Google Scholar
• Dobesh PP. Economic implications of inadequate treatment of venous thromboembolism and potential solutions. J Pharm Pract 2014;27:178–86
   PubMedGoogle Scholar
• Landman GW, Gans RO. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2011;364:1178
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–52
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799–808
   PubMed Web of Science ®Google Scholar
• Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406–15
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm. [Last accessed February 2015]
   Google Scholar
• Boehringer Ingelheim. FDA approves Pradaxa® (dabigatran etexilate mesylate) for treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism. Available from http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/04-07-14-fda-approves-pradaxa-dabigatran-etexilate-mesylate-treatment-reduction-risk-of-recurrence-deep-venous-thrombosis-pulmonary-embolism.html. [Last accessed February 2015]
   Google Scholar
• U.S. FDA approves Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy. Available from http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy. [Last accessed February 2015]
   Google Scholar
• FDA approves anti-clotting drug Savaysa. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm. [Last accessed February 2015]
   Google Scholar
• Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 2012;129:392–400
   PubMed Web of Science ®Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;24432872
   Google Scholar
• Efron B, Tibshirani RJ. An introduction to the bootstrap. 1st edition. New York: Chapman & Hall; 1993
   Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829–37
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645–53
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hill J, Hess GP. Dabigatran etexilate is associated with shorter hospital length of stay compared to warfarin in patients with nonvalvular atrial fibrillation. Circulation 2012;5:A282
   Google Scholar
• Cowper PA, Pan W, Anstrom K, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of apixaban therapy on resource use in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. J Am Coll Cardiol 2013;61:E1576
   Web of Science ®Google Scholar
• Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975–82
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441–5
   PubMed Web of Science ®Google Scholar
• Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677–81
   PubMed Web of Science ®Google Scholar
• Lozano F, Trujillo-Santos J, Barrón M, et al. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg 2014;59:1362–7.e1
   Google Scholar
• Othieno R, Abu Affan M, Okpo E. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2007:CD003076
   Google Scholar
• Spencer FA, Emery C, Joffe SW, Pacifico L, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401–9
   PubMed Web of Science ®Google Scholar